Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy

Date: October 19, 2020
Issue #: 
1609Summary: 
The antisense oligonucleotide viltolarsen (Viltepso–
NS Pharma) has received accelerated approval
from the FDA for treatment of Duchenne muscular
dystrophy (DMD) in patients who have mutations of the
dystrophin gene that are amenable to exon 53 skipping
(DMD-53). It is the second drug to be approved for this
indication; the antisense oligonucleoti de golodirsen(Vyondys 53) was approved in 2019.

Source: The Medical Letter - October 9, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research